A Multicenter, Open-label, Single-sequence Cross-over Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension Switching From an Oral Stable Dose of Selexipag
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Selexipag (Primary) ; Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 27 Sep 2017 Planned End Date changed from 28 Feb 2018 to 9 Jul 2018.
- 27 Sep 2017 Planned primary completion date changed from 28 Feb 2018 to 9 Jul 2018.
- 27 Sep 2017 Planned initiation date changed from 1 Oct 2017 to 21 Dec 2017.